Zacks Investment Research downgraded Corium International Inc (NASDAQ:CORI) to Sell in a report released today.
- Updated: October 16, 2016
Just yesterday Corium International Inc (NASDAQ:CORI) traded -3.14% lower at $5.54. Corium International Inc’s 50-day moving average is $5.72 and its 200-day moving average is $4.61. The last stock price is up 13.66% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 10,477 shares of CORI traded hands, down from an average trading volume of 41,700
Zacks Investment Research has downgraded Corium International Inc (NASDAQ:CORI) to Sell in a report released on 10/11/2016.
Previously on 5/3/2016, WBB Securities released a statement about Corium International Inc (NASDAQ:CORI) increased the target price from $0.00 to $11.00. At the time, this indicated a possible upside of 1.12%.
Recent Performance Chart
Corium International Inc has 52 week low of $3.14 and a 52 week high of $9.93 and has a market capitalization of $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 6 brokerages have issued a research note on the company. The average stock price target is $14.67 with 0 brokerages rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Corium International Inc (NASDAQ:CORI)
Corium International, Inc. is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules. Its Corplex and MicroCor platforms address the shortcomings of traditional transdermal drug delivery. Its marketed products include Clonidine TDS, which is a treatment for hypertension; Fentanyl TDS, which is a treatment for management of chronic pain, and Crest Whitestrips are a series of five products for oral care. Its Twirla is designed to deliver both hormones at levels comparable to low-dose oral contraceptives. Its MicroCor hPTH(1‑34) is a transdermal system designed to use its MicroCor technology to provide the delivery of parathyroid hormone.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.